Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
A large study shows risperidone raises stroke risk in patients with dementia, even those without cardiovascular disease — ...
GlobalData on MSN
FDA approves Teva and Medincell’s bipolar I disorder treatment
The once-a-month extended-release injectable suspension incorporates Medincell's copolymer technology. Credit: PhotobyTawat/Shutterstock.com. Teva Pharmaceuticals and ...
10d
Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed
Teva Pharmaceuticals and Medincell recently announced that the FDA has approved UZEDY® (risperidone), a once-monthly ...
The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release injectable suspension) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best high volume stocks to buy according to Wall Street ...
The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment ... (Wall Street Journal via MSN) The investigational ADHD drug dexmethylphenidate is under FDA review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback